Samba participates in 'CPhI Worldwide'... unveils new slogan 'Accelerating Excellence'

Participated in Solo Booth Every Year Since 2018
Promoting Bispecific Antibody 'S-Dual' and New Drug Discovery 'Developic'

Overview of the Samsung Biologics booth installed at the 'CPhI Worldwide 2022' event in Frankfurt, Germany (Photo by Samsung Biologics)

[Asia Economy Reporter Chunhee Lee] Samsung Biologics announced on the 31st that it will participate in the world’s largest bio and pharmaceutical conference, ‘CPhI Worldwide 2022 (Convention on Pharmaceutical Ingredients Worldwide 2022).’

CPhI is the largest global bio and pharmaceutical industry event held annually in rotation among major European countries. This year, it will be held in Frankfurt, Germany, from the 1st to the 3rd of next month (local time) for a total of three days. During the event, more than 2,500 companies from 170 countries worldwide are expected to participate, with over 40,000 visitors anticipated at the exhibition hall.

Samsung Biologics has participated every year since 2018 with a dedicated booth, except for the 2020 event which was held online due to the COVID-19 pandemic. This year, the company plans to install a large-scale booth of 238㎡ in a prime location within the exhibition hall, offering new customer experiences and conducting business networking through various content and events.

In particular, Samsung Biologics unveiled its new slogan, ‘Accelerating Excellence.’ This slogan expresses Samsung Biologics’ overwhelming speed and quality competitiveness. It reflects the company’s determination to leap beyond being the world’s number one global contract manufacturing organization (CMO) in production capacity achieved within 10 years of business entry, to becoming a global bio-leading company.

On the booth’s walls, large panels showcasing the company’s innovations and achievements at a glance will be installed, along with various video contents highlighting the competitiveness of its contract development and manufacturing organization (CDMO) business. Detailed explanations will be provided through wall graphics about the world’s largest single-facility Plant 4, which began operations just 23 months after groundbreaking, significantly shortening construction time, as well as the new bispecific antibody platform ‘S-DUAL’ and the drug candidate discovery platform ‘DEVELOPICK.’

One side of the booth will feature a meeting kiosk to efficiently accommodate visitors seeking partnership discussions by providing VIP customer dedicated guidance services. Additionally, Samsung Biologics will provide visitors with tablets containing brochures and videos to enhance understanding of its services, while also conducting surveys to investigate industry demands and trends.

On the 11th, Lee Jae-yong, Vice Chairman of Samsung Electronics (right), visited the Samsung Biologics Songdo Campus in Yeonsu-gu, Incheon, and inspected Plant 4 together with John Rim, CEO of Samsung Biologics. (Photo by Samsung Electronics)

During the exhibition, Samsung Biologics plans to actively engage with key figures in the bio and pharmaceutical industry, including participating as a sponsor of major events.

Banners of Samsung Biologics will be installed throughout the exhibition hall to focus on raising brand awareness within the global bio and pharmaceutical industry and Europe. On the first day of the event, the 1st, Samsung Biologics will exclusively host an ‘Exclusive Networking Session’ to conduct in-depth networking with potential clients and maximize sales performance. This event, held for the first time at CPhI this year, offers lunch and close networking in a separate space within the exhibition hall for a selected group of attendees personally chosen by the host. Samsung Biologics plans to promote the competitiveness of Plant 4 and discuss business partnerships for securing global customers at this event.

On the same day, Kevin Sharp, Head of the Global Sales Center, will deliver a speaking session titled ‘What are the key considerations in choosing the right CDMO partner?’ where he will discuss important factors in selecting a CDMO company and Samsung Biologics’ competitive strengths. On the second day, James Choi, Head of the Global Information Marketing Center, will present on ‘Samsung Biologics’ commitment to ESG as a first leader among CDMOs,’ covering Samsung Biologics’ ESG (Environmental, Social, and Governance) management strategy and response to climate change for sustainable corporate growth.

This content was produced with the assistance of AI translation services.